List of Vaccines Companies in Georgia - 12

Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company, focuses on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The company’s lead product candidate is AL001 for the treatment of Alzheimer’s and other neurodegenerative diseases and psychiatric disorders. It is also developing AL002, a cell-based therapeutic vaccine, which seeks to restore the ability of the patient’s immunological system to Alzheimer’s. The company was incorporated in 2016 and is headquartered in Tampa, Florida.

GeneCure Biotechnologies is a biotechnology company that focuses on developing gene therapy based technologies to treat genetic and acquired human diseases.

The Georgia Genomics and Bioinformatics Core (GGBC) is the University of Georgia (UGA) core laboratory for nucleic acid sequencing and bioinformatics. Theirmission includes research support, education, and training. Theirservices are available to university and industry researchers.Theirservices encompass the range of genomic techniques and applications, sequencing technologies, and bioinformatics analyses. GGBC operates multiple platforms for short-, long-, and single-molecule sequencing reads (i.e., Illumina MiSeq and NextSeq, PacBio Sequel, and Oxford Nanopore MinIon). Theyalso write letters of support (LOS) to offer theircapabilities and expertise for grant applications submitted to funding agencies.

GeoVax Labs, Inc., (NASDAQ: GOVX) is a clinical-stage biotechnology company developing human vaccines against infectious diseases using our Modified Vaccinia Ankara - Virus-Like Particle (MVA-VLP) vaccine platform. Our current development programs are focused on vaccines against COVID-19; Hemorrhagic Fever viruses such as Ebola (Zaire, Sudan), Lassa and Marburg; Malaria and Zika virus; and, Human Immunodeficiency Virus (HIV). We have also initiated programs to develop a broadly applicable immunotherapy against tumor associated antigen MUC1 that is expressed of many solid tumor types including breast, ovarian, gastric, liver, pancreas, renal and lymph nodes and immunotherapy to treat human papilloma virus (HPV)-induced cancers.

Inhibikase Therapeutics (Nasdaq: IKT) is a clinical-stage pharmaceutical company focused on developing and commercializing small-molecule kinase inhibitor therapeutics that modify Parkinson's disease and drive functional reversal inside and outside of the brain. Inhibikase is headquartered in Atlanta, Georgia with additional offices in Boston, Massachusetts.

The Institute of Bioinformatics's mission is to facilitate cutting-edge interdisciplinary research in bioinformatics/computational biology and its application. We train graduate students to tackle complex biological problems which utilize omics or other complex data types.

Metaclipse Therapeutics is a preclinical stage biotech company developing novel cancer therapies that are tailored to each patient and their specific tumor. The Company’s first ‘personalized’ cancer therapy is for triple negative metastatic breast cancer. Metaclipse intends to commercialize its products through licensing agreements with major pharmaceutical companies after establishing their safety and effectiveness in early clinical trials by year-end 2019.

Micron Biomedical, Inc. is a clinical-stage biopharmaceutical company on a rapid path to bring to market drugs and vaccines that are formulated into a proprietary patch technology that simplifies and improves the way actives are delivered, stored, and distributed. This technology is designed to increase patient access to drugs and vaccines that would otherwise require expert injection and to improve safety and efficacy by skin targeting.

Piezo Therapeutics aims to transform the delivery of nucleic acid medicines to enable improved safety, affordability, and scalability. Piezo is developing a uniquely engineered platform that uses electric pulses and microneedles to deliver a broad range of therapeutics inside the body. Its piezoelectric technology offers improved safety and efficacy, and is simple, cost-effective, and rapid to produce at scale. Founded by experts in the field of drug delivery and commercial translation, Piezo's diverse team aims to help translate the next generation of nucleic acid medicines. For more information, please visit www.piezotx.com or email partnerships@piezotx.com.

Cancer patients get one chance to save their tumor tissue. Don't throw it away. Unfortunately most tissue is routinely discarded, but SpeciCare aims to change that. Your tumor tissue is as unique as a fingerprint, and holds the key to more effective, precision treatments, leading to improved outcomes, and a better quality of life. We work with cancer patients, and their care team, to uncover treatment options not available without SpeciCare's innovative protocol. Call today to speak to one of our patient advocates. We care about you.

Vernagen aims to discover and develop mRNA based therapeutics using highly advanced mRNA technologies. Our current pipeline includes vaccine platforms targeting various emerging pathogens and biologics platforms aiming to replace current protein based therapeutics. Our mRNA platforms employ multiple innovative chemical and biological components to enhance their therapeutic efficacy and safety.